dsm-firmenich to sell MEG-3 fish oil business to KD Pharma Group

The transaction includes dsm-firmenich’s MEG-3 business for the Food & Beverage, Dietary Supplement and Pharma markets, together with the production facilities in Piura, Peru and Mulgrave, Canada

dsm-firmenich, an innovator in nutrition, health, and beauty, today announces the sale of its MEG-3 fish oil business (MEG-3 business) to KD Pharma Group SA (KD Pharma), a contract development and manufacturing organisation (CDMO) active in pharmaceutical and nutritional lipids. As part of the transaction, dsm-firmenich will obtain a minority stake of 29 per cent in KD Pharma’s parent company O³ Holding GmbH.  

Following its strategic portfolio review, as announced, dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business. This will allow dsm-firmenich to focus its lipids activities on its unique algae-based Omega-3 portfolio while continuing to offer MEG-3 fish oils for the Early Life Nutrition markets as well as MEG-3 powders.

The transaction includes dsm-firmenich’s MEG-3 business for the Food & Beverage, Dietary Supplement and Pharma markets, together with the production facilities in Piura, Peru and Mulgrave, Canada. The MEG-3 business represented approximately €170 million in sales in 2023, with approximately 200 employees who will transfer to KD Pharma.  

This transaction is expected to be completed towards the end of 2024 and is subject to customary regulatory approvals.